A number of biomarkers are used to evaluate the duration of the epileptic seizure and the interictal period following neuronal injury. Invasive diagnostic methods are increasingly being replaced by peripheral or minimally invasive biomarkers that give results faster and are more secure.
Purpose
We aimed to evaluate serum glial fibrillary acidic protein (GFAP), S100B, and ubiquitin C-terminal hydrolase (UCHL-1) levels in children with epilepsy.
Methods
Our study included 3 groups: a nonrefractory epilepsy group, a refractory epilepsy group, and a control group. The GFAP, S100B, and UCHL-1 levels in serum samples collected 2-24 hours after the last seizure were analyzed using enzyme-linked immunosorbent assays.
Results
A total of 69 children participated in the study, with 35 participants in the refractory epilepsy group, 18 in the nonrefractory epilepsy group, and 16 in the control group. The GFAP values in the refractory (25.4 ng/mL) and nonrefractory (26.1 ng/mL) epilepsy groups were found to be statistically significantly higher than those in the control group (17.9 ng/mL; P = .001). The S100B values were found to be significantly higher in the refractory epilepsy group (34.13 pg/mL) than in both the control group and the nonrefractory epilepsy group (28.05 pg/mL; P = .028). No significant differences were observed in the UCHL-1 levels between the 3 groups.
Conclusions
We conclude that the observed differences may be due to the increased expression of S100B and GFAP caused by increased and repetitive neuronal damage in refractory epilepsies compared with nonrefractory epilepsies.
ElhadyMYounessERAbuShadyMM, et al.Circulating glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 as markers of neuronal damage in children with epileptic seizures. Childs Nerv Syst. 2021;37:879-884. https://doi.org/10.1007/s00381-020-04920-z
2.
SumadewiKTHarkitasariSTjandraDC. Biomolecular mechanisms of epileptic seizures and epilepsy: a review. Acta Epileptologica. 2023;5:28. https://doi.org/10.1186/s42494-023-00137-0
3.
YangZWangKKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38:364-374. https://doi.org/10.1016/j.tins.2015.04.003
ReevesSAHelmanLJAllisonAIsraelMA. Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci U S A. 1989;86:5178-5182. doi:https://doi.org/10.1073/pnas.86.13.5178
6.
LapingNJTeterBNicholsNRRozovskyIFinchCE. Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors. Brain Pathol. 1994 Jul;4(3):259-275. doi: https://doi.org/10.1111/j.1750-3639.1994.tb00841.x
7.
HolEMPeknyM. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121-130. https://doi.org/10.1016/j.ceb.2015.02.004
8.
OecklPHalbgebauerSAnderl-StraubS, et al.Glial fibrillary acidic protein in Serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481-488. https://doi.org/10.3233/JAD-180325
9.
SuWChenHBLiSHWuDY. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson’s disease patients. Clin Neurol Neurosurg. 2012;114:372-375. https://doi.org/10.1016/j.clineuro.2011.11.002
10.
LyubimovaNVTimofeevYSMitrofanovAABekyashevAKGoncharovaZAKushlinskiiNE. Glial fibrillary acidic protein in the diagnosis and prognosis of malignant glial tumors. Bull Exp Biol Med. 2020;168:503-506. https://doi.org/10.1007/s10517-020-04741-9
11.
BishopPRoccaDHenleyJM. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J. 2016;473:2453-2462. https://doi.org/10.1042/BCJ20160082
12.
ReynoldsJPJimenez-MateosEMCaoL, et al.Proteomic analysis after Status epilepticus identifies UCHL1 as protective against hippocampal injury. Neurochem Res. 2017;42:2033-2054. https://doi.org/10.1007/s11064-017-2260-6
13.
WangKKYangZSarkisGTorresIRaghavanV. Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries. Expert Opin Ther Targets. 2017;21:627-638. https://doi.org/10.1080/14728222.2017.1321635
14.
MondelloSPalmioJStreeterJHayesRLPeltolaJJerominA. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol. 2012;12:85. https://doi.org/10.1186/1471-2377-12-85
15.
DonatoRSorciGRiuzziF, et al.S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta Mol Cell Res. 2009;1793:1008-1022. https://doi.org/10.1016/j.bbamcr.2008.11.009
16.
KligmanDMarshakDR. Purification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci U S A. 1985;82:7136-7139. doi:https://doi.org/10.1073/pnas.82.20.7136
17.
MaitiRMishraBRJenaMMishraANathSSrinivasanA. Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial. J Neurol. 2018;265:2594-2601. https://doi.org/10.1007/s00415-018-9026-1
18.
SandlerSJIFigajiAAAdelsonPD. Clinical applications of biomarkers in pediatric traumatic brain injury. Childs Nerv Syst. 2010;26:205-213. https://doi.org/10.1007/s00381-009-1009-1
19.
Van EldikLJWainwrightMS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci. 2003;21:97-108.
20.
JacksonRGMSamraGSRadcliffeJClarkGHPriceCP. The early fall in levels of S-100 β in traumatic brain injury. Clin Chem Lab Med. 2000;38(11)1165-1167. https://doi.org/10.1515/CCLM.2000.179
21.
RaabeASeifertV. Protein S-100B as a serum marker of brain damage in severe head injury: Preliminary results. Neurosurg Rev. 2000;23:136-138. https://doi.org/10.1007/PL00011944
22.
KleindienstAHesseFBullockMRBuchfelderM. The neurotrophic protein S100B: Value as a marker of brain damage and possible therapeutic implications. Prog Brain Res.2007;161:317-325. https://doi.org/10.1016/S0079-6123(06)61022-4
23.
GeyerCUlrichAGräfeGStachBTillH. Diagnostic value of S100B and neuron-specific enolase in mild pediatric traumatic brain injury. J Neurosurg Pediatr. 2009;4:339-344. https://doi.org/10.3171/2009.5.PEDS08481
24.
LiangKGMuRZLiuYJiangDJiaTTHuangYJ. Increased serum S100B levels in patients with epilepsy: a systematic review and meta-analysis study. Front Neurosci. 2019;13:456. https://doi.org/10.3389/fnins.2019.00456
25.
GazzoloDGrutzfeldDMichettiF, et al.Increased S100B in cerebrospinal fluid of infants with bacterial meningitis: relationship to brain damage and routine cerebrospinal fluid findings. Clin Chem. 2004;50:941-944. https://doi.org/10.1373/clinchem.2003.021048
26.
GazzoloDAbellaRMarinoniE, et al.Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. Cardiovasc Hematol Agents Med Chem. 2009;7:108-126. https://doi.org/10.2174/187152509787847119
27.
SimaniLElmiMAsadollahiM. Serum GFAP level: a novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks. Seizure. 2018;61:41-44. https://doi.org/10.1016/j.seizure.2018.07.010
28.
GurnettCALandtMWongM. Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia. 2003;44:1455-1458. https://doi.org/10.1046/j.1528-1157.2003.21603.x
29.
TybirkLHviidCVBKnudsenCSParknerT. Serum GFAP - pediatric reference interval in a cohort of Danish children. Clin Chem Lab Med. 2023 May 18;61(11):2041-2045. doi: https://doi.org/10.1515/cclm-2023-0280. PMID: 37195150.
30.
MocholMTaubøllEAukrustPUelandTAndreassenOASvalheimS. Serum markers of neuronal damage and astrocyte activity in patients with chronic epilepsy: Elevated levels of glial fibrillary acidic protein. Acta Neurol Scand.2023;2023:5. https://doi.org/10.1155/2023/7246373
31.
LiYWangZZhangB, et al.Cerebrospinal fluid ubiquitin C-terminal hydrolase as a novel marker of neuronal damage after epileptic seizure. Epilepsy Res. 2013;103:205-210. https://doi.org/10.1016/j.eplepsyres.2012.08.001
32.
PapaLMittalMKRamirezJ, et al.Neuronal biomarker ubiquitin C-terminal hydrolase detects traumatic intracranial lesions on computed tomography in children and youth with mild traumatic brain injury. J Neurotrauma. 2017;34:2132-2140. https://doi.org/10.1089/neu.2016.4806
33.
RamezaniFBahrami-AmiriABabahajianAShahsavari NiaKYousefifardM. Ubiquitin C-terminal hydrolase-L1 (UCH-L1) in prediction of computed tomography findings in traumatic brain injury; a meta-analysis. Emerg (Tehran). 2018;6(1):e62. PMID: 30788389; PMCID: PMC6368936.
34.
SteinhoffBJTumaniHOttoM, et al.Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res. 1999;36:75-82. https://doi.org/10.1016/S0920-1211(99)00026-1
35.
ChangC-CLuiC-CLeeC-C, et al.Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol. 2012;12:15. https://doi.org/10.1186/1471-2377-12-15
